SAN DIEGO, March 18, 2019 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil is hosting an event on Medical Cannabis at the Fera Palace Hotel in the Historic Center of Salvador, Bahia on March 19.
According to a report by New Frontier Data, the Brazilian medical cannabis market could grow to $1.4 billion annually if CBD products are approved for other uses.
At the event, medical cannabis experts will discuss the landscape of medical cannabis in Brazil, the potential therapeutic applications of cannabidiol (CBD) and legal issues of cannabis in Brazil.
“As the first company to receive import approval from the National Sanitary Surveillance Agency (Anvisa) to import CBD products, we are very proud to have continued to experience such tremendous growth over the past few months,” said HempMeds® Brasil Vice President Caroline Heinz. “We’ve had great success with our previous educational events and hope that this event will be well received by both consumers and doctors as well.”
Speakers at the event will include Medical Marijuana, Inc. CEO Dr. Stuart Titus, HempMeds® Brasil Director of Medical Affairs, Dr. Junior Gibelli, HempMeds® Brasil Vice President Caroline Heinz, HempMeds® Brasil Director of Institutional Relations Norberto Fischer, HempMeds® Brasil Director of Legal Affairs Ricardo Handro and several patients sharing their personal stories of using CBD.
“The cannabis industry is taking off in Latin America more than we could have ever expected,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “That said, there are still many misconceptions about CBD and our mission is to help people become more educated about what it is and its potential health benefits.”
To learn more about the event, please visit https://hempmeds.com.br/.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
About HempMeds® Brasil
HempMeds® Brasil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson’s, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brasil works on additional approvals for other indications. www.hempmeds.com.br.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer CMW Media